Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Express Scripts
Boehringer Ingelheim
AstraZeneca

Last Updated: June 25, 2022

Oncopeptides Ab Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ONCOPEPTIDES AB, and what generic alternatives to ONCOPEPTIDES AB drugs are available?

ONCOPEPTIDES AB has one approved drug.

There are five US patents protecting ONCOPEPTIDES AB drugs.

There are seventy-six patent family members on ONCOPEPTIDES AB drugs in twenty-seven countries.

Summary for Oncopeptides Ab
International Patents:76
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Oncopeptides Ab

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No See Plans and Pricing See Plans and Pricing
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No 10,543,274 See Plans and Pricing See Plans and Pricing
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No 10,285,946 See Plans and Pricing Y See Plans and Pricing
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No 10,322,182 See Plans and Pricing Y See Plans and Pricing
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No 10,869,928 See Plans and Pricing Y See Plans and Pricing
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No 6,992,207 See Plans and Pricing Y Y See Plans and Pricing
Oncopeptides Ab PEPAXTO melphalan flufenamide hydrochloride POWDER;INTRAVENOUS 214383-001 Feb 26, 2021 DISCN Yes No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
AstraZeneca
Medtronic
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.